Randomized, double-blind, multicenter trial of hydrogen water for Parkinson’s disease.
Asako Yoritaka, Chigumi Ohtsuka, Tetsuya Maeda, Masaaki Hirayama, Takashi Abe, Hirohisa Watanabe, Hidemoto Saiki, Genko Oyama, Jiro Fukae, Yasushi Shimo, Taku Hatano, Sumihiro Kawajiri, Yasuyuki Okuma, Yutaka Machida, Hideto Miwa, Chikako Suzuki, Asuka Kazama, Masahiko Tomiyama, Takeshi Kihara, Motoyuki Hirasawa, Hideki Shimura, Eisei Oda, Mikako Ito, Kinji Ohno, Nobutaka Hattori · Movement disorders : official journal of the Movement Disorder Society · 2018
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In with PD and treated with levodopa, a previous randomized, doubleblind study showed that drinking 1,000 mL of H₂ water per day for 48 weeks significantly improved the total Unified Parkinson’s Disease Rating Scale (UPDRS) scores of patients with PD and treated with levodopa. There were no significant differences in the change in the total UPDRS score from baseline to the 72nd week between the H₂-water group (1.6 ± 14.0 [mean ± standard deviation]) and the placebo water group (0.8 ± 9.6; t test, P =.939; analysis of variance, P =.538; Table 1). These findings add human evidence supporting molecular hydrogen's therapeutic potential for Parkinson's disease.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in with PD and treated with levodopa. A previous randomized, doubleblind study showed that drinking 1,000 mL of H₂ water per day for 48 weeks significantly improved the total Unified Parkinson’s Disease Rating Scale (UPDRS) scores of patients with PD and treated with levodopa. There were no significant differences in the change in the total UPDRS score from baseline to the 72nd week between the H₂-water group (1.6 ± 14.0 [mean ± standard deviation]) and the placebo water group (0.8 ± 9.6; t test, P =.939; analysis of variance, P =.538; Table 1).
What the Researchers Studied
The researchers studied with PD and treated with levodopa. The study used a randomized, double-blind, placebo-controlled human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
Reported treatment duration: 48 weeks. A previous randomized, doubleblind study showed that drinking 1,000 mL of H₂ water per day for 48 weeks significantly improved the total Unified Parkinson’s Disease Rating Scale (UPDRS) scores of patients with PD and treated with levodopa. There were no significant differences in the change in the total UPDRS score from baseline to the 72nd week between the H₂-water group (1.6 ± 14.0 [mean ± standard deviation]) and the placebo water group (0.8 ± 9.6; t test, P =.939; analysis of variance, P =.538; Table 1). Molecular hydrogen (H₂) water has been shown to reduce oxidative stress and dopaminergic neuronal cell loss in a PD model.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for Parkinson's disease and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, double-blind, placebo-controlled human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was with PD and treated with levodopa. The study used a randomized, double-blind, placebo-controlled human clinical trial. The reported treatment duration was 48 weeks.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.